USA flag logo/image

An Official Website of the United States Government

DOMINANT PEPTIDE INHIBITORS OF PLANT VIRUS REPLICATION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54526
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43GM062684-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
DELTAGEN PROTEOMICS, INC.
DELTAGEN PROTEOMICS, INC. 615 ARAPEEN DR, STE 300 SALT LAKE CITY, UT 84108
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: DOMINANT PEPTIDE INHIBITORS OF PLANT VIRUS REPLICATION
Agency: HHS
Contract: N/A
Award Amount: $99,174.00
 

Abstract:

DESCRIPTION (Verbatim from Applicant's Abstract):We have developed a technology for somatic cell genetics that leads rapidly to genetic agents that modulate cellular phenotypes. The technology utilizes genetic assays in combination with perturbagens, peptides that inhibit specific biochemical processes in cells, causing a phenotypic shift. Our perturbagen technology is potentially able to endow plants with novel phenotypes that would be very difficult to obtain by conventional plant breeding. The primary objective of the proposed research is to explore the use of perturbagen methods to identify peptide aptamers that confer resistance to the model viral pathogen tobacco etch virus (TEV), a member of the economically important potyviruses. Phase I research involves: (1)The identification of peptides that bind to TEV NIa and HC-Pro proteins and TEV RNA genome using the technology developed at Arcaris (specifically, perturbagen libraries) via modified yeast two-and three-hybrid systems. (2)The expression of these peptides in cultured tobacco cells to identify peptides that inhibit TEV replication. Protoplasts derived from these tobacco cells will be infected with transcripts of TEV that has been modified to include the b-glucuronidase (GUS) gene in its genome. The impact of these peptides on TEV replication will be monitored by GUS activity. PROPOSED COMMERCIAL APPLICATION: In contrast to viral sequence-derived resistance, perturbagen technology circumvents any potential risks associated with the expression of virus-derived transgenes. This approach has the potential to engineer highly durable virus resistance in plants by expression of peptides that interfere with the function several essential viral proteins. In addition, this technology can be used to rapidly identify perturbagens with fungicidal, bacteriocidal, and insecticidal properties that cna be expressed in plants.

Principal Investigator:

Robert W. Sandrock

Business Contact:


8013030300
KAMB@ARCARIS.COM
Small Business Information at Submission:

ARCARIS, INC.
615 ARAPEEN DR, STE 300 SALT LAKE CITY, UT 84108

EIN/Tax ID: 870560505
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No